ArticleProceedings of the National Academy of Sciences of the United States of America1992
gp330 associates with a 44-kDa protein in the rat kidney to form the Heymann nephritis antigenic complex.
Article in Proceedings of the National Academy of Sciences of the United States of America, 1992. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 141 citations in OpenAlex.
- Article
- Combination therapy of cisplatin with cilastatin enables an increased dose of cisplatin, enhancing its antitumor effect by suppression of nephrotoxicity.Scientific reports · 2021Article
- Megalin Blockade with Cilastatin Suppresses Drug-Induced Nephrotoxicity.Journal of the American Society of Nephrology : JASN · 2017Article
- The role of complement in membranous nephropathy.Seminars in nephrology · 2013Review
- The atherogenic lipoprotein Lp(a) is internalized and degraded in a process mediated by the VLDL receptor.The Journal of clinical investigation · 1997Article
- Pathogenic antibodies inhibit the binding of apolipoproteins to megalin/gp330 in passive Heymann nephritis.The Journal of clinical investigation · 1997Article
- Identification of the second cluster of ligand-binding repeats in megalin as a site for receptor-ligand interactions.Proceedings of the National Academy of Sciences of the United States of America · 1997Article
- Endocytic trafficking of megalin/RAP complexes: dissociation of the complexes in late endosomes.Molecular biology of the cell · 1997Article
- Defective forebrain development in mice lacking gp330/megalin.Proceedings of the National Academy of Sciences of the United States of America · 1996Article
- Mapping rat megalin: the second cluster of ligand binding repeats contains a 46-amino acid pathogenic epitope involved in the formation of immune deposits in Heymann nephritis.Proceedings of the National Academy of Sciences of the United States of America · 1996Article
- Ligand selectivity of 105 kDa and 130 kDa lipoprotein-binding proteins in vascular-smooth-muscle-cell membranes is unique.The Biochemical journal · 1996Article
- RAP, a specialized chaperone, prevents ligand-induced ER retention and degradation of LDL receptor-related endocytic receptors.The EMBO journal · 1996Article
- Induction of passive Heymann nephritis with antibodies specific for a synthetic peptide derived from the receptor-associated protein.The Journal of experimental medicine · 1996Article
- Molecular analysis of the pathological autoimmune antigens of Heymann nephritis.The American journal of pathology · 1996Review
- Induction of Heymann nephritis with a gp330/megalin fusion protein.The American journal of pathology · 1996Article
- Evidence that epithelial glycoprotein 330/megalin mediates uptake of polybasic drugs.The Journal of clinical investigation · 1995Article
- Level of receptor-associated protein moderates cellular susceptibility to pseudomonas exotoxin A.Infection and immunity · 1995Article
- Functional expression of low density lipoprotein receptor-related protein is controlled by receptor-associated protein in vivo.Proceedings of the National Academy of Sciences of the United States of America · 1995Article
- Animal models for disorders of hepatic lipoprotein metabolism.Journal of molecular medicine (Berlin, Germany) · 1995Review
- Antibodies to the 280-kd coated pit protein, target of teratogenic antibodies, produce alterations in the traffic of internalized proteins.The American journal of pathology · 1994Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 2 countries.
Funding
Abstract
Using antibodies isolated from glomeruli of nephritic rats we have previously identified a 330-kDa cell surface glycoprotein (gp330) as a major pathogenic antigen of Heymann nephritis (HN), an experimental model of human membranous glomerulonephritis. Recently, we have isolated a cDNA clone, C14, encoding a polypeptide that contains a pathogenic epitope of HN responsible for the initiation of the disease. Subsequently, another protein, alpha 2-macroglobulin receptor-associated protein (alpha 2-MRAP), which is a subunit of the receptor for human alpha 2-macroglobulin/low density lipoprotein receptor-related protein (LRP), was shown to possess a high degree of sequence homology to the C14 protein (C14p). In this report, we have investigated the relationship between gp330, C14p, and alpha 2-MRAP. Immunoprecipitation studies demonstrate that gp330 forms a heterodimeric association with a 44-kDa polypeptide that is stable to detergent extraction and long-term centrifugation. Further, immunoblotting analysis on the purified complex indicates that the 44-kDa associated protein shares immunological identity to C14p and alpha 2-MRAP. In addition, antibodies eluted from glomeruli of HN rats and antibodies to a C14 fusion protein immunoprecipitated gp330 and the 44-kDa protein, demonstrating that the epitopes responsible for the initial events of HN are accessible within the complex. Based on these data, three models are proposed to explain how pathogenic epitopes in the gp330-44-kDa, HN antigenic complex may be presented at the cell surface and initiate the onset of HN.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.